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Abstract 
In collaboration with Heidi Shaffer, one of the occupational therapists on staff at the MultiCare 
lymphedema clinic in Gig Harbor, Washington, we sought to answer the question “Which patient-reported 
outcome assessments are most valid and reliable in measuring health-related quality of life (HRQoL) in 
patients with lymphedema?” We conducted a systematic literature review to answer this question. In 
reviewing selected databases, 19 articles were chosen to appraise the evidence supporting psychometric 
properties and clinical utility of 10 HRQoL assessments used for patients with lymphedema. The Disability of 
the Arm, Shoulder and Hand (DASH) and Lymphedema Life Impact Scale (LLIS) assessments demonstrated 
stronger evidence for test-retest reliability, internal consistency, and clinical utility for use in a lymphedema 
practice setting in the U.S. than other assessments.  
The next step was to bring the findings back to Heidi and her colleagues to answer questions they 
had about using recommended assessments to generate G-codes for Medicare reporting and to explore 
strategies that could be used to implement these recommended assessments within MultiCare’s electronic 
medical record (EMR) system. We provided an in-service on our findings for MultiCare’s lymphedema 
therapists, at which time we distributed laminated calculation cards for converting DASH scores to G-code 
modifiers and obtained feedback through a satisfaction survey. In addition, we met with the Director of 
Physical Medicine and Rehabilitation at MultiCare, Sherri Olsen, to determine the best process for 
embedding the LLIS and the DASH into their EMR and identify future research needs. Additional steps will 
include follow up on the progress and outcomes of embedding the assessments into the EMR and further 
research to address changes in the literature, HRQoL assessments for other diagnostic populations, and 
determining the efficacy and benefits of prehab treatments. 
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Executive Summary 
This year-long review effort began by asking the question, “Which functional outcome measures 
used by lymphedema therapists are best for determining G-codes?” In order to meet the needs of our 
collaborating clinician, Heidi Shaffer from the MultiCare lymphedema clinic in Gig Harbor, our research 
question was changed to, “Which patient-reported outcome assessments are most valid and reliable in 
measuring health-related quality of life in patients with lymphedema?” Currently, HRQoL measures specific 
to patients with lymphedema are lacking psychometric rigor. These instruments are particularly critical 
following a recent mandate by Medicare to produce G-codes, which report function-related outcomes. Our 
aim with this literature review was to provide local lymphedema therapists with recommended HRQoL 
assessments that could be used within the facility’s electronic medical record (EMR) system to generate 
Medicare G-codes. 
We conducted a systematic literature review to appraise the evidence supporting the psychometric 
properties and clinical utility of 10 HRQoL assessments used for patients with lymphedema. To determine 
which assessments to include in our review, we first identified HRQoL assessments commonly used in 
lymphedema research. Next, we reviewed selected databases and chose 19 articles that met our inclusion 
criteria (i.e. the study was peer-reviewed, analyzed one or more of the selected assessments) and exclusion 
criteria (i.e. published prior to 1980, study population did not include patients with cancer and/or 
lymphedema, and not available in English). Each article was categorized using American Occupational 
Therapy Association (AOTA) levels of evidence and the research pyramid. All articles were considered and 
reviewed by five individuals for inclusion in this review. 
After critically appraising the articles, we determined that the DASH and the LLIS assessments 
demonstrated the strongest evidence for test-retest reliability, internal consistency, and clinical utility for use 
in a lymphedema practice setting in the U.S. We concluded there was strong evidence to recommend the 
DASH and modest evidence to recommend the LLIS for use with patients with lymphedema. Specifically, 
this review supports the use of the DASH for patients with lymphedema when lymphedema is secondary to 
breast cancer. For patients with lymphedema not secondary to breast cancer, the LLIS was found to be the 
most appropriate assessment at this time. Practitioners should evaluate the characteristics of each assessment 
against a client's specific presentation (e.g. comorbidities, upper limb versus lower limb, etc.) to select the 
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most appropriate assessment tool. Use of psychometrically sound assessments arms practitioners with 
objective data to quantify function and progress of treatment. This demonstrates the effects of intervention to 
third-party payers for purposes of reimbursement. In addition, such assessments provide cohesion across 
therapists and settings and communicate intervention outcomes with a variety of disciplines along the 
continuum of care. 
To translate our findings into clinical practice, we conducted an in-service presentation to MultiCare 
lymphedema therapists in Tacoma, WA., at which time we distributed laminated calculation cards for 
converting DASH scores to G-code modifiers. At the conclusion of our presentation, we obtained feedback 
through a satisfaction survey. Based on results from the survey, we concluded that we adequately informed 
clinicians about psychometric properties of lymphedema HRQoL assessments. We also concluded that some 
clinicians did not find the G-code modifier card useful, and that they were unlikely to begin using the DASH 
if they were not already. In addition, we met with the Director of Physical Medicine and Rehabilitation at 
MultiCare, Sherri Olsen, to determine the best process for embedding the LLIS and the DASH into their 
EMR system. Next steps will include follow up on the progress and outcomes of embedding the assessments 
into their EMR. Future research is needed to address changes in the literature, to identify HRQoL assessments 
for other diagnostic populations, and to determine the efficacy and benefits of prehab treatments. 
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Focused Question: 
Which patient-reported outcome assessments are most valid and reliable in measuring health-related 
quality of life (HRQoL) in patients with lymphedema? 
 
Collaborating Occupational Therapy Practitioner: 
Heidi Shaffer, OTR/L, CLT  
 
Prepared By: 
Bonnie Blair, OTS; Gina Dellino, OTS; Jennifer Thomas, OTS 
 
Chair: 
Tatiana Kaminsky, PhD, OTR/L 
 
Course Mentor: 
George Tomlin, PhD, OTR/L, FAOTA 
 
Date Review Completed: 
May 9, 2017 
 
Clinical Scenario: 
At the MultiCare lymphedema clinic in Gig Harbor, Washington, occupational therapists work with 
patients to manage lymphedema: a chronic but manageable condition caused by the buildup of lymph 
fluid when the lymphatic system is damaged or blocked (Bulley, Gaal, Coutts, Blyth, Jack, Chetty … 
Tan, 2013). The majority of patients are referred from oncology seeking treatment for lymphedema 
consequent to their cancer treatment. Typically, the goal of therapy is to manage lymphedema through 
manual drainage, care for damaged skin, and compression garments and bandages for an improved 
HRQoL (Bulley et al., 2013). In 2013, therapists were required to report functional outcomes via G-codes 
for patients insured by Medicare part B (Doucet, 2013). For patients with lymphedema, HRQoL is an 
important indicator of function (Morgan, Franks, & Moffatt, 2005). There is a lack of HRQoL measures 
specific to patients with lymphedema that have psychometric rigor (Mitchell, Gleeson, DiCecco, 
2008).   Instruments that have completed psychometric testing are important for validating, guiding, and 
improving the quality of intervention. In addition, these instruments are particularly critical to 
occupational therapists during a time of increased demands by third party payers to produce function-
related outcomes, an integral pillar of occupational therapy practice (Doucet, 2014). Currently, the 
MultiCare lymphedema clinic is transitioning to using the Lymphedema Life Impact Scale to better 
understand and report on functional outcomes of treatment. 
This critically appraised topic will help to establish the most reliable and valid HRQoL measures to be 
used for patients with lymphedema by reporting on existing instruments and their psychometric 
properties. This information will serve the collaborating therapist in selecting the most appropriate 
outcome measure for clinical use. The therapists at the Multicare lymphedema clinic in Gig Harbor wish 
to know which HRQoL assessments are most reliable and valid to meet the demands of third party payers 
and the requirements for G-code reporting set forth by Medicare. 
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Review Process 
Procedures for the selection and appraisal of articles 
Inclusion Criteria: 
Articles were chosen if: 
 The study examined at least one of the ten HRQoL assessments and derivatives used with the 
lymphedema population: LLIS, ULL-27, Lymph-ICF, LYMQOL, LyQLI, SF-36, EORTC QLQ-
BR23, FACT-B+4, FLIC, or DASH and provided psychometric data. 
 The study was peer-reviewed. 
Exclusion Criteria: 
Articles were excluded if: 
 The study was published prior to 1980. 
 The study population did not include any patients with cancer and/or lymphedema. 
 The study is not available in English. 
 
Search Strategy 
Categories Key Search Terms 
Patient/Client 
Population 
Lymphedema, Breast Cancer 
Intervention 
(Assessment) 
LLIS (Lymphedema Life Impact Scale), ULL-27, Lymph-ICF, LYMQOL 
(Lymphedema Quality of Life), LyQLI (Lymphedema Quality of Life 
Inventory), SF-36 Health Survey, NHP (Nottingham Health Profile), EORTC 
QLQ-C30 (EORTC QCQ-BR23), FACT-B, FLIC (Functional Living Index-
Cancer), or DASH (Disability Arm Shoulder Hand) 
Quality of Life, Functional Outcome Measures 
Comparison 
 
Outcomes Psychometrics: reliability and validity 
Development 
Investigation 
Evaluation 
 
Databases and Sites Searched 
AJOT, BJOT, CJOT 
CINAHL 
ProQuest 
Research Gate (Publications) 
Cochrane 
MEDLINE 
OT Seeker, OT Search 
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Google Scholar 
PubMed 
References of References 
Citation Tracking 
 
Quality Control/Review Process: 
Our initial search began by asking the question, “Which functional outcome measures used by 
lymphedema therapists are best for determining G-codes?” After briefly reviewing the literature and in 
consult with our chairperson and professors, we decided to eliminate G-codes from our research question 
and focus on outcome components of lymphedema treatment. Since lymphedema is a chronic condition, 
one of the main goals of treatment is improved quality of life. As such, our research question was 
changed to, “Which patient-reported outcome assessments are most valid and reliable in measuring 
health-related quality of life in patients with lymphedema?” 
 
Based on this question, we generated a list of specific HRQoL assessments that are currently used by 
lymphedema therapists. We then looked to see if psychometric studies had been completed and if the 
assessment was feasible within the United States; we eliminated all measures that failed to meet these 
criteria. Finally, we generated a list of key terms that included common diagnoses seen in this patient 
population and terms directly from the clinical question to guide our search. 
 
Results of Search 
 
Table 1. Search Strategy of databases. 
Search Terms Date Database Initial 
Hits 
Articles 
Excluded 
Total Selected for 
Review 
Functional outcome measures 
AND lymphedema 
9/22/2016 CINAHL 1 0 1 
Functional outcome measures 
AND lymphedema 
10/9/2016 ProQuest 1558 19 1 
Functional outcome measures 
AND lymphedema 
10/09/2016 Cochrane 14 14 0 
Not relevant or did 
not meet inclusion 
criteria. 
Functional outcome measures 
AND lymphedema 
10/09/2016 MEDLINE 0 0 0 
Functional outcome measures 
AND lymphedema 
10/09/2016 OT Search 0 0 0 
Functional outcome measures 
AND lymphedema 
10/09/2016 OT Seeker 0 0 0 
Functional outcome measures 
AND lymphedema 
10/09/2016 Google Scholar 10,700 20 0 
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Functional outcome measures 
AND lymphedema AND 
psychometrics 
10/09/2016 Google  
Scholar 
1,150 26 1 
“Lymphedema functional 
outcome measure 
psychometrics” 
10/09/2016 Google Scholar 0 0 0 
Lymphedema functional 
outcome measure psychometrics 
10/09/2016 Google Scholar 1,200 35 0 
Lymphedema AND reliability 10/15/2016 AJOT 6 6 0 
Irrelevant 
Lymphedema Life Impact Scale 10/18/2016 CINAHL 0 0 0 
Lymphedema Quality of Life 
Inventory (LyQLI)-Development 
and investigation of validity and 
reliability 
10/18/2016 Primo 2 2 0 
Lymphedema Life Impact Scale 10/18/2016 Cochrane 5 5 0 
Nottingham Health Profile 10/18/2016 CINAHL 259 39 1 
Irrelevant 
Nottingham Health Profile AND 
breast cancer 
10/18/2016 CINAHL 2 2 0 
EORTC AND reliability 10/18/2016 CINAHL 70 70 0 
EORTC AND lymphedema 10/18/2016 CINAHL 5 5 0 
Lymph-ICF AND reliability 10/18/2016 Primo 4 2 1   
Duplicates 
Lymph-ICF  10/18/2016 CINAHL 2 2 0 
Duplicates 
Lymph-ICF 10/18/2016 PubMed 5 5 0  
Irrelevant or 
duplicates 
ULL-27 AND reliability 10/18/2016 PubMed 0 0 0 
ULL-27 AND validity 10/18/2016 PubMed 1 1 0 
Duplicates 
ULL-27 10/18/2016 PubMed 2 2 0 
Lymphedema AND reliability 10/18/2016 CINAHL 41 41 0  
Duplicates 
Lymphedema, quality of life 10/21/2016 Primo 573 52 0 
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Lymphedema, quality of life 
inventory 
10/21/2016 Primo 237 43 0 
Lymphedema life impact scale 10/21/2016 Google Scholar 9, 920 19 1 
Lymphedema, quality of life, 
validity, reliability 
10/21/2016 PubMed 15 14 1 
LBCQ AND lymphedema 10/21/2016 PubMed 8 8 0 
LBCQ AND lymphedema 10/21/2016 ProQuest 17 17 0 
(1 used for 
background) 
LBCQ AND reliability 10/21/2016 CINAHL 1 1 0 
LBCQ AND validity 10/21/2016 CINAHL 2 0 0 
(2 used for 
background) 
LBCQ and lymphedema 10/21/2016 Research Gate 
(publications) 
9 9 0 
(FACT-B) AND reliability 10/21/2016 PubMed 20 20 0 
(1 used for 
reference tracking) 
LYMQOL 10/21/2016 PubMed 1 1 0 
Lymphedema quality of life 
questionnaire 
10/21/2016 CINAHL 2 2 0 
Lymphedema quality of life 
(LYMQOL) 
10/21/2016 Google Scholar 71 70 1 
Irrelevant or 
duplicates 
Psychometric AND 
Lymphedema 
10/21/2016 CINAHL 6 6  0 
Psychometric evaluation of the 
SF-36 health survey 
10/22/2016 PubMed 2 2 2 
SF-36 AND lymphedema AND 
validity 
10/22/2016 CINAHL 5 5 0 
Nottingham Health Profile, 
validity, reliability 
10/22/2016 Primo 145 50 0 
Functional living index cancer 
AND validity 
10/22/2016 PubMed 113 20 0  
disability arm shoulder hand 
AND validity 
10/22/2016 PubMed 179 40 0 
DASH AND psychometrics 10/22/2016 PubMed 91 20 0 
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Lymphedema AND reliability 10/22/2016 BJOT 177 40 0 
Duplicates or 
Irrelevant 
Lymphedema AND reliability  10/22/2016 CJOT 1 1 0 
Irrelevant 
Total number of articles used in review from database searches = 8 
Table 2. Articles from citation tracking. 
 
Article Date Database Initial 
Hits 
Articles 
Excluded 
Total Selected for 
Review 
Davies, Ryans, Levenhage & 
Perdomo (2014) 
9/22/2016 ProQuest 17 16 1 
Total number of articles used in review from citation tracking = 1 
 
Table 3. Articles from reference tracking. 
 
From Article Date Articles 
Referenced 
Articles 
Excluded 
Total Selected for 
Review 
Davies, Ryans, Levenhage & 
Perdomo (2014) 
10/18/2016  31 27 4  
Wilson, R. W., Hutson, L. M. & 
VanStry, D. (2005) 
10/18/2016 37 36 1 
Maratia, S., Cedillo, S. & Rejas, J. 
(2016) 
10/21/2016 62 57 5  
Total number of articles used in review from reference tracking = 10 
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CAT Table 4: Descriptive Studies 
Author, 
Year, 
Journal 
Abbreviatio
n 
Study 
Objectives 
Study 
Design/ 
Level of 
Evidence 
Assessmen
ts or 
screens 
being 
compared 
Population/ Setting Psychometrics Summary of 
results 
Limitations 
Brady, 
Cella, Mo, 
Bonomi, 
Tulsky, 
Lloyd, 
Deasy, 
Cobleigh, 
Shiomoto 
(1997), JCO 
Validation of 
the FACT-B 
AOTA 
level: IV 
 
Pyramid 
level: D2 
FACT-B 
- 
FACT-G  
 
BC-
Subscale 
 
FLIC 
 
PSR 
First sample:  
Patients w/ advanced 
BC, completed FACT-B 
version 1, treated at 
Rush-Presbyterian-St. 
Luke’s Medical Center. 
Patients tested twice 
over 2 months. 
 
N = 47  
 
Second sample: 
Adults w/ BC, w/o brain 
metastasis, not using 
psychotropic drugs, and 
completed version 3 of 
the FACT-B; recruited 
from 3 medical centers 
 
N = 295 
 
Cronbach’s α: 
 0.63-0.90 
 
Test-retest reliability: 
Correlation coefficients: 
0.88 for BC-Subscale, 
0.89 for TOI-PFB, & 
0.85 for FACT-B total 
score, indicating high 
degree of stability (3 to 7 
days) 
 
Validity: 
The first sample 
demonstrated sensitivity 
to change on the total 
score, the PWB subscale, 
FWB subscale, and the 
BC-Subscale with (F 
(df=12,78) = 2.59: p 
=0.006) 
 
Construct validity: 
FLIC (r=0.87; p < 
0.001), FACT-G total 
score (r=0.86; p < 
0.001),  TOI-PFB 
(r=0.86; p < 0.001), and 
BC-Subscale (r=0.53; p 
< 0.001) for first sample. 
 
Known-groups 
validity: 
FACT-B is 
appropriate for use 
in oncology clinical 
trials and clinical 
practice. 
Demonstrates ease 
of use, brevity, 
reliability, validity, 
and sensitivity to 
change. 
Must be administered 
in its entirety; no 
limitations listed or 
found in the study 
design. 
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F(18, 784) =10.27; p < 
0.001 
Coster, 
Poole, & 
Fallowfield 
(2001), 
BCRT 
Document the 
validation of 
the FACT-B 
w/ the 
addition of 
the 4-item 
arm subscale 
and the 
sensitivity to 
effects of arm 
morbidity.   
Prospective 
longitudina
l 
correlation 
study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
FACT-B+4 
 
FACT-B 
Group 1 
Population/Setting: 
Participants in phase 1 of 
the ALMANAC study, 
under the care of breast 
cancer surgeons in the 
UK. 
  
N: 279 
 
Group 2 
Population/Setting: 
Women with known 
chronic arm morbidity 
attending a 
lymphoedema clinic.  
 
N: 29 
Cronbach’s α: 
0.62 for BC subscale, 
0.88 for total FACT-B+4 
score, 0.83 for arm 
subscale. 
 
Test-Retest reliability: 
Total arm subscale 
(r=0.93), FACT-B+4 
(r=0.97) over 5-day 
period for group 2.  
Group 2 scored lower on 
all QoL subscales, 
except EWB, than a 
subset of group 1.  
 
Non-parametric chi-
squared: 
On all arm items was 
significant, p=0.001, 
89.36-13.47, df=4) 
between the 2 groups.  
 
Sensitivity to change 
over time:  
Was significantly lower 
4 weeks post baseline 
(prior to surgery) 
measures for mean 
scores (p=0.001), arm 
subscales increased 
significantly from 
baseline measures 
(p=0.01). 
 
 
 
 
FACT-B+4 appears 
to be 
psychometrically 
sound. It is suitable 
to be used in 
longitudinal surgical 
trials. Reliability is 
comparable to 
previous validation 
studies. Good test-
retest reliability. 
There is reliable 
discrimination 
between patients w/ 
and w/o severe arm 
morbidity. Arm 
subscale and FACT-
B+4 were sensitive 
to changes in arm 
condition over time. 
Patients found the 
scale easy to 
complete. 
Study failed to 
identify limitations of 
the design, including 
patients recruited 
instead of randomly 
selected. Study only 
looked at change 
over 12 weeks.  Not 
necessarily 
generalizable to men.  
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Davies, 
Brockopp, 
& Moe 
(2015), RO  
 
Determine 
the 
psychometric
s, including 
test-retest and 
internal 
consistency 
for using the 
DASH with 
BC survivors 
with 2° 
lymphedema. 
Retrospecti
ve 
Correlation
al Study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
DASH Population: Women 
diagnosed with BC, with 
secondary lymphedema. 
Mean age of 60yo 
 
Setting: Outpatient 
rehabilitation department 
of a Magnet re-
designated community 
hospital. 
 
N:163 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cronbach’s α: 
Initial evaluation=0.97, 
30-day re-
evaluation=0.92, 
discharge=0.92 
 
Test-retest: 
 ICC=0.97 
The DASH is found 
to have strong test-
retest reliability and 
internal consistency 
for measuring upper 
extremity function 
among BC survivors 
with lymphedema. 
Clients’ recall of 
previous answers on 
the assessment may 
have affected test-
retest outcomes. First 
study to look at this 
demographic with the 
DASH.  
Not necessarily 
generalizable to men 
with lymphedema.  
Devoogdt, 
Groef, 
Hendrickx, 
Damstra, 
Christiaanse
n, 
Geraerts… 
Kampen, 
(2014), 
PT 
Develop the 
Lymph-ICF-
LL (phase 1) 
and to 
determine the 
reliability and 
validity of the 
Lymph-ICF-
LL (phase 2) 
Correlation
al study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
Lymph-
ICF-LL 
- 
Compared 
to: 
SF-36 
FLQA-I 
Phase 1 
Population: 
Men (20%) & women 
(80%) averaging 58.7 
yo. who spoke Dutch 
Diagnosed w/ 2° LE 
lymphedema 
 
Setting: 
Leuven Lymphoedema 
Center (Belgium) 
 
N= 20 
 
Phase 2 
Reliability 
Test-retest: 0.69-0.94 
(correlation coefficient) 
Internal Consistency: 
0.82-0.97 (Cronbach α) 
Measurement 
Variability: acceptable; 
SEM = 5.9 - 12.6 
 
Validity 
Content: good; questions 
understandable (93% of 
participants), 
questionnaire 
The Lymph-ICF-LL 
has strong face, 
construct, and 
content validity. It 
has strong reliability 
with high intra-class 
correlation 
coefficients. 
Developers provide 
suggestions for 
improving 4 
questions that rated 
moderate for test-
retest reliability via 
administration. 
Only tested Dutch 
version of measure. 
Phase 1 participant 
diagnoses differed 
from those of phase 
2. Responsiveness of 
the Lymph-ICF-LL 
and known-groups 
validity was not 
tested for.   
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Population:  
Men (20%) & women 
(80%) averaging 51 yo. 
and spoke Dutch 
Diagnosed w/ 1° or 2° 
LE lymphedema 
 
Setting: 
Lymphedema clinic at 
Nij Smellinghe Hospital 
(Netherlands) (n= 11), 
Leuven Lymphedema 
Center (Belgium) (n= 19 
 
N= 30 
 
 
 
 
 
 
 
 
 
comprehensive (90% of 
participants) 
Construct: good; all 
hypotheses for 
convergent and divergent 
validity accepted 
(correlation coefficients 
for convergent validity 
ranged from -0.46 to       
-0.86 and divergent 
validity ranged from 
0.04 to -0.32). 
(24/28 questions 
very strong – 
strong). 
Devoogdt, 
Kampen, 
Geraerts, 
Coremans, 
& 
Christiaens 
(2011), PT 
Investigate 
the reliability 
and validity 
of data 
collected by 
the final 
version of the 
Lymph-ICF 
Correlation
al study 
  
AOTA 
level: IV, 
Pyramid 
level : D2 
Lymph-
ICF  
- 
Compared 
to SF-36 
Population: Women w/ 
BC having undergone 
unilateral axillary 
dissection <12 months 
prior to study. Dutch 
speaking. 
 
Setting: 
Department of 
Physiotherapy of the 
University Hospital, 
Leuven   
 
N= 90 (n= 60 w/ 
lymphedema, n=30 w/o 
lymphedema) 
Reliability 
Test-retest:  
r =0.65 -0.93  
Internal Consistency: 
> 0.77 (Cronbach’s α) 
Measurement 
Variability: 
acceptable; 
SEM = 4.8-12.5 
 
Validity 
Content: good; questions 
understandable, clear 
scoring system for 88% 
of participants, 
lymphedema complaints 
The final version of 
the Lymph-ICF is a 
reliable and valid 
Dutch questionnaire 
to assess functional 
problems (as 
defined by the 
WHO-ICF) for 
patients with 
lymphedema 2° to 
axillary dissection. 
Study did not 
investigate 
responsiveness. 
Focus on Dutch 
version, limits 
generalizability to the 
USA. Lack of detail 
for participant 
characteristics in 
phase 1 and use of 
researcher developed 
questionnaire to 
determine content 
validity introduces 
bias and perhaps 
confounding 
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mentioned by 85% of 
participants 
Construct: good; 
convergent validity 
confirmed by 5 domains 
on Lymph-ICF 
correlating strongest w/ 
5 expected domains of 
SF-36; divergent 
confirmed 3/5 
hypotheses accepted. 
 
variables (within 
participant 
characteristics). 
Participants may 
have had trouble 
distinguishing 
between 
complications due to 
lymphedema versus 
BC treatment. 
Women only. 
Keeley, 
Crooks, 
Locke, 
Veigas, 
Riches 
Hilliam, 
(2010), JL 
Describe the 
validation of 
a condition-
specific QoL 
measure for 
lymphedema 
of the limbs. 
Retrospecti
ve 
correlation
al study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
LYMQOL  
- 
Compared 
to: 
EORTC 
QLQ-C30 
New patients presenting 
to the clinic. 
Mean age: 58 years (SD 
16.4 years). 
78% were women, 
bilateral leg swelling 
was the most frequently 
reported (43.8%), 26.8% 
reported unilateral am 
swelling, 27.7% 
unilateral leg swelling, 
1.5% reporting 
combination of arm and 
leg swelling 
 
N = 209 
 
Face validity: 
Was confirmed with 
questionnaire, content 
validity established via 
phenomenological 
interview of 22 patients 
 
Correlation coefficient: 
for arm ranged from 
0.689-0.937 and for leg 
from 0.644-0.788 
respectively w/ 
comparable domains in 
the EOC QLQ-C30. 
LYMQOL is a 
validated QoL 
assessment for use 
w/ people w/ limb 
lymphoedema 
Limitations not 
listed, full 
psychometric data 
findings from 
previous 2004 study 
not listed 
Klernäs, 
Johnsson, 
Horstmann, 
Kristjanson, 
& Johansson 
(2015), QLR 
Reduce the 
SLQOLI 
from 188 
items to 45 
items to 
create the 
LyQLI. 
Determine 
psychometric
s of the 
LyQLI, 
Correlation
al Study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
LyQLI 
- 
Adapted 
from 
SLQOLI 
- 
Compared 
against SF-
36 
Population/Setting: 
Outpatients from the 
registers of the 
lymphedema units at 
Skane University 
Hospital and Red Cross 
Hospital, Solna, Sweden. 
Adults diagnosed with 
lymphedema >6months.  
 
Inter-rater reliability: 
Using ICC for physical, 
psychosocial and 
practical domains on the 
shorter instrument were 
0.88 (p<0.01), 0.87  
(p<0.01), and 0.87 
(p<0.01). 
 
 
 
The LyQLI shows 
promise for clinical 
settings and future 
studies for those 
with lymphedema.  
Shown to have very 
good internal 
consistency 
reliability. 
Concurrent validity 
was shown through 
No patient expert 
group evaluated in 
final questionnaire. 
Percentage of 
missing items for the 
patients ranged from 
0 to 14.6%, mean 
scores were used 
instead. Patients 
instructed not to 
receive additional 
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including 
stability over 
time and 
concurrent 
validity.   
N: 200 (100/site) 
contacted, 130 
participated.  
Cronbach’s α:  
0.88, 0.92, 0.88 – 
Physical, psychosocial, 
& practical domains, 
respectively. 
 
Concurrent Validity: 
Scores of the three 
domains of the shortened 
LyQLI with scores of the 
PCS and MCS in the SF-
36 were all rs > 0.60. 
 
correlation with the 
SF-36 for all 
domains. 
treatment, not 
verifiable. Patients 
may have improved 
due to time of year or 
expectations effect. 
Did not assess the 
sensitivity of the 
LyQLI. 
 
 
 
 
Launois, 
Megnigbeto, 
Pocquet, & 
Alliot 
(2002), L 
Administer 
validity 
testing as a 
final step in 
development 
of ULL-27  
Correlation
al study 
 
AOTA 
Level:  
IV 
Pyramid 
Level: D2 
 
 
ULL-27 
- 
Compared 
against SF-
36, GSI, 
ACS, GCI 
Population: 
Women aged > 18 yo. 
(average age = 61 yo.) of 
all educational levels 
previously treated with 
surgery, radiotherapy, 
chemotherapy, or 
hormone therapy.  
 
Diagnoses: 
Upper limb lymphedema 
stages 1-4, 2° to BC. 
47% had a history of 
lymphangitis.  
 
Setting: multiple centers 
  
N = 301 
 
 
Internal Consistency: 
Physical = 0.93 
Psychological= 0.86 
Social = 0.82 
(Cronbach’s α) 
 
 
Effect Size in patients 
who improved clinically:  
Physical = 0.58 
Psychological= 0.62 
Social= 0.38 
 
ULL-27 is shown to 
be valid and 
reliable. Scores for 
physical and social 
dimensions 
significantly 
correlated to illness 
severity. Social 
dimension is 
sensitive to clinical 
changes in 
lymphedema while 
physical and 
psychological 
dimensions do not 
change in clinically 
stable patients.  
Measurement tool 
was developed in 
France for French 
speaking patients 
limiting 
generalizability for 
practitioners in other 
countries. 
Methodology & 
results for 
comparison to SF-36 
are brief, limiting 
ability to reproduce 
methods or compare 
results. Setting is 
unclear. Poor quality 
of research 
translation from 
French to English 
language affecting 
interpretation of 
results. 
Morrow, 
Lindke, & 
Black  
(1992), QLR 
Examine 
psychometric
s of the FLIC, 
including 
Correlation
al Study 
 
AOTA 
level: IV 
FLIC Population: Patients 
being treated w/ 
chemotherapy.  
Age: 18-76.  
 
Construct validity:  
18/22 questions had 
factor loading > 0.40 on 
only 1 of 5 factors. 4 
questions addressing 
FLIC appears to be 
a valid and 
internally consistent 
instrument. There is 
strong evidence for 
The study failed to 
identify limitations in 
the design, such as all 
clients recruited from 
one cancer center. 
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construct 
validity 
Pyramid 
level: D2 
Setting: University of 
Rochester Cancer 
Center. 
 
N: 489, originally 
recruited 530 
cancer had loading > 
0.40 on 2+ factors.  
 
Criterion-related 
validity: Low side-
effects and anxiety result 
in higher QoL scores. 
Females had higher 
physical & social 
functioning scores. 
Internal consistency: 
Cronbach’s α = 0.90 
(original sample), 0.94 
(validation sample) 
construct validity, 
and factors were 
sensitive to 
meaningful 
differences. The 4 
cancer related 
questions should be 
omitted to create a 
better fit of the data 
to the factor model.   
The study looked 
broadly at cancer, 
limiting 
generalizability to 
lymphedema. 
Patoo, 
Allahyari, 
Moradi, & 
Payandeh 
(2015), 
APJCP 
Assess the 
validity of the 
FACT-B 
when used for 
Iranian 
women w/ 
BC. 
Correlation
al study  
 
AOTA 
level: IV 
Pyramid 
level: D2 
FACT-B 
(Persian 
Version) 
-  
compared 
against 
HADS 
anxiety and 
depression 
and the 
EORTC 
QLQ-C30 
Population/Setting: 
Women recruited from 
oncology clinics and 
hospitals in Iran. 
Pathologic diagnosis of 
cancer.  
 
N: 300 
Internal consistency: 
Cronbach’s α: 0.93-0.63 
for subscales, 0.92 total 
scale.  
 
Convergent validity:  
All interscale 
correlations p<0.01, 
except SFWB and PWB 
Discriminant validity: 
correlation between all 
Persian FACT-B 
subscales and HADS 
statistically significant.  
Concurrent and 
construct validity: 
Except SFWB, all 
subscales of FACT-B 
significantly correlated 
w/ EORTC-QLQ-C30 
Fit indices showed 
modest fit of the model. 
 
 
 
 
The Persian version 
of FACT-B is 
reliable and valid in 
assessing HRQoL of 
Iranian BC patients.  
Validation of a 
translated version of 
FACT-B, not 
original. Cultural 
differences of Iranian 
women, including 
taboo nature of 
speaking about 
sexuality limits 
generalizability to 
USA. Study failed to 
identify specific 
limitations. Limited 
information 
regarding patient 
recruitment process.   
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Sprangers, 
Groenvold, 
Arraas, 
Frnklin, 
Velde, 
Mulle… 
Aaronson, 
(1996), JCO 
 
Develop a BC 
specific QoL 
questionnaire 
used in 
tandem w/ the 
EORTC 
QLQ-C30 
 
 
AOTA 
level:  
IV  
 
Pyramid 
level: 
D2 
 
QLQ-BR23 
 
Dutch Sample: 
Participants had BC and 
were receiving either 
radiotherapy or 
chemotherapy. 
Setting: Antoni van 
Leeuwenhoek Hospital, 
Amsterdam 
 
N = 170 
 
Spanish Sample: 
Participants had BC and 
were receiving either 
radiotherapy or 
chemotherapy. 
Setting: Hospital de 
Navarra, Pamplona 
 
N = 168 
 
American Sample: 
Participants had BC and 
were either about to start 
treatment or were in 
follow up care.  
Setting: M.D. Anderson 
Cancer Center, Houston, 
TX 
 
N = 158 
 
 
 
 
 
 
 
 
Reliability: 
Cronbach’s α:  
Dutch = 0.57 - 0.89 
Spanish = 0.46 – 0.94 
American = 0.70 – 0.91 
 
Validity: 
Spanish effect sizes: 
medium (0.60-0.68) 
Dutch effect sizes: 
medium-large (0.43-1.1) 
American sample did not 
achieve statistical 
significance. 
 
 
 
 
Validity 
demonstrated by 
test’s ability to 
discriminate 
amongst subgroups 
with different 
clinical statuses and 
across cultures. 
Reliability lowest in 
Spanish sample and 
highest in American 
sample.  
Scores measuring 
clinical state of 
health were not 
completely 
comparable as 
Spanish patient 
information was 
provided by 
physician and Dutch 
sample was 
interviewer based. 
Questions about 
sexuality were 
considered too 
intrusive for some 
female participants 
and were 
unanswered.  
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Van de Pas, 
Biemans, 
Boonen, 
Viehoff & 
Neumann 
(2015), P 
Test the 
psychometric 
properties 
and validate 
use of a 
Dutch 
translation of 
the 
LYMQOL 
Questionnaire  
Correlation
al study 
 
AOTA 
Level: IV 
Pyramid 
level: D2 
LYMQOL 
SF-36 
60 patients diagnosed at 
an academic institution 
completed questionnaire. 
Response rate was 
88.2%, 70% were 
women.  
Mean age: 60 
SD: 15.6 years 
Range: 19-92. Most had 
bilateral leg 2° 
lymphedema. Classified 
according to duration of 
lymph: 
0-5 yrs: 19.4% 
5-10 yrs: 22.4% 
10-20 yrs: 28.4% 
20+ ys: 29.9% 
 
Most patients wore 
compression stockings 
Internal Consistency: 
Cronbach’s α: 0.89 
 
Test-retest reliability: 
Excellent, w/ rho >0.8 
for all domains, and 
overall QoL was good, 
w/ rho >0.7 
 
 
Validity: 
The LYMQOL 
correlated well w/ the 
PCS and moderately 
well with the MCS of the 
SF-36 
The Dutch 
LYMQOL is a 
feasible, reliable, 
and valid tool in the 
assessment of 
HRQoL in patients 
w/ LE lymphedema. 
 
Generalizability 
limited due to non-
randomized sample 
and Dutch population 
Viehoff, 
Genderen, & 
Wittink,(200
8), L 
Validate a 
version of the 
ULL-27 
translated to 
Dutch 
Correlation
al study 
 
AOTA: IV 
Pyramid: 
D2 
ULL-27 
(Dutch 
version) 
- 
Compared 
against the 
SF-36 
Population: 
Women (mean age= 59) 
fluent in Dutch. 94% had 
axillary surgery. 
Diagnosed w/ unilateral 
edema of the UE 
 
Setting: 
29 lymphedema 
physiotherapy specialist 
practice settings 
 
N= 84 
 
Comparison Population:  
An age-matched group 
of women without 
symptoms 
 
N=61 
Internal consistency: 
good; all > 0.70 
(Cronbach’s α) 
 
Item domain internal 
consistency sufficient 
except for 2 questions 
(#20 & #22) 
 
Concurrent Validity: 
domains of Dutch ULL-
27 significantly 
correlated to 5 of 8 
corresponding SF-36 
domains  
No distinction 
between 4 grades of 
severity in Dutch 
version (inconsistent 
with original version 
of ULL-27),  similar 
internal consistency 
(good) to original 
version, physical 
domain of ULL-27 
poorly correlated to 
SF-36 
Participant 
characteristics 
(amongst types of 
severity) do not 
match that of the 
original validation 
study making direct 
comparison 
impossible; 
comparison group 
consisted of 
physiotherapist’s 
friends and family 
introducing bias 
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Weiss & 
Daniel 
(2015), L 
 
Assess the 
reliability and 
validity of the 
LLIS as a 
condition-
specific 
instrument 
for persons 
with 
lymphedema. 
Correlation
al cohort 
study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
LLIS 
- 
Compared 
to: 
LYMQOL 
EORTC 
QLQC30 
DASH 
LEFS 
Population/Setting: 
Adult patients w/ 
lymphedema (except 
controls which 
comprised of patients at 
risk for lymphedema) 
recruited from 
lymphedema therapy 
clinics across the US.  
 
N=102 
 
 
 
 
Internal consistency: 
Cronbach’s α: .841-.926 
 
Test-retest 
reliability:  .97-.99 
 
Construct validity: 
r = .706-.830 
 
 
 
 
 
The LLIS was 
demonstrated to be a 
valid and reliable 
QoL tool for 
assessing severity of 
impairment among 
patients w/ 
lymphedema. 
 
 
Most participants 
were white females 
limiting 
generalizability 
across gender and 
race.  
Wilson, 
Hutson, & 
VanStry 
(2005), PT 
Assess 
convergent 
validity and 
discriminativ
e validity of 
SF 36 and 
FLIC 
Correlation
al study 
 
AOTA 
level: IV 
Pyramid 
level: D2 
RAND 36-
Item Health 
Survey 
(SF-36) 
 
FLIC 
Population: Women w/ 
BC, who received 
surgical intervention > 
3mo prior.  
Age: 18-65yo.  
 
Setting: National Cancer 
Institute-designated 
Comprehensive Cancer 
Center 
 
N: 110 (n=32 w/ 2º 
lymphedema) 
Bivariate correlations: 
SF-36 mental & physical 
component tau-b=0.247. 
SF-36 mental component 
& FLIC total tau-
b=0.490. SF-36 physical 
component & FLIC total 
tau-b=0.556. 
 
Convergent/Divergent 
Validity:  
Comparisons of pairs of 
subscales of QoL 
domains showed 
convergent correlations 
in the physical domain 
(𝑥2=20.48, p<0.001), 
mental well-being 
domain (𝑥2=7.68, 
p<0.01), & social 
functioning (𝑥2=4.45, 
p<0.05). However, 
convergence within the 
general health dimension 
was not significant 
Neither 
questionnaire can 
replace the other for 
women with BC. 
The modest 
correlations between 
the SF-36 and FLIC 
suggest they 
measure somewhat 
different aspects of 
HRQoL. The FLIC 
was more sensitive 
to differences in 
EWB. Both FLIC 
and SF-36 were able 
to distinguish 
deficits in physical 
functioning in the 
group with 
lymphedema.  
Clinic data 
influencing HRQoL 
was not collected, 
limiting 
generalizability. Only 
compared two 
instruments, limiting 
convergent validity 
measures. Population 
limited to women w/ 
BC more than 3 
months post-surgical 
intervention.  
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(𝑥2=3.27, p < 0.1), 
indicating these similarly 
named subscales 
measure different QoL 
dimensions in this 
sample. 
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CAT Table 5: Systematic Reviews  
Author(s), Year Study 
Objectives 
Study Design/ 
Level of 
Evidence 
Number of Papers 
Included, Inclusion and 
Exclusion Criteria 
Outcome 
Measures 
Summary of Results Limitations 
Davies, Ryans, 
Levenhage, & 
Perdomo (2014), 
RO 
Identify outcome 
measures 
targeting QoL 
and function 
specific to UE 
secondary 
lymphedema, 
review 
psychometrics, 
and make clinical 
recommendations 
Systematic 
Review 
 
AOTA Level: I 
 
Pyramid Level: 
D1 
Papers Included: 42 
 
Inclusion Criteria: 
UE secondary lymphedema, 
female, adult, breast 
neoplasm,  
 
Exclusion Criteria: primary 
lymphedema, LE, venous, 
male gender, lack of 
psychometric properties 
FACT-B +4, 
DASH, ULL-27, 
Lymph-ICF, 
LYMQOL 
FACT-B+4 
Highly recommended due to 
test-retest reliability, overall 
internal consistency; 
unknown clinical utility  
DASH 
Highly recommended for 
test-retest reliability, internal 
consistency, validity, and 
sensitivity to change 
(MCID=10.2); good clinical 
utility 
ULL-27 
Unable to recommend at this 
time  
Lymph-ICF 
Unable to recommend at this 
time (no sensitivity reported, 
lack of clinical use in U.S.) 
LYMQOL 
Unable to recommend at this 
time (in development phase) 
 
 
Limited to UE assessments 
and BCRL, Recommendations 
based on Breast Cancer EDGE 
Task Force ratings and 
definitions for clinical utility 
could contain bias. 
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Oliveira, Costa, 
Gafundes, & 
Cabral (2015), 
QLR 
Identify BC 
specific 
questionnaires 
that have been 
cross-culturally 
adapted and 
critically 
analyzed for 
quality of 
translation, 
adaptation, and 
evaluation of 
measurement 
properties 
Systematic 
Review 
 
AOTA level: I 
  
Pyramid level: 
D1 
Papers Included:  
24 
Inclusion Criteria:  
Studies from any year or 
language assessing BC-
specific QoL questionnaires 
translated into a language 
besides source language. 
Studies exclusive to women 
with BC.   
 EORTC QLQ-
BR23 
 FACT-B 
 FACT-B+4 
 IBCSG 
 LSQ-32 
 QLICP-BR 
 
Shortcomings in global BC 
QoL instruments. Over half 
of articles had no 
information for translation 
and cross-cultural 
adaptation.  EORTC QLQ-
BR23 in Spanish and Korean 
highest level of translation 
and cultural adaptation. 
Internal consistency doubtful 
in 15 articles. Construct 
validity adequate in 3 studies 
(FACT-B, EORTC, & QLQ-
BR23). 4 of 8 articles 
positively reported 
reliability.  
Studies evaluated by one set 
of guidelines. Cross-cultural 
validation and measurement 
properties of a QoL 
questionnaire are complex and 
subject to misinterpretation.  
Pusic, Cemal, 
Albornoz, Cano, 
Sulimanoff, 
Hernandez, 
Massey, Cordeiro, 
Morrow, & 
Mehrara 
(2013), JCS 
Identify studies 
describing 
HRQOL 
outcomes in 
BCRL patients, 
assess quality of 
studies, & assess 
PRO instruments 
Systematic 
Review 
 
AOTA Level 1 
 
Pyramid level 
D1 
39 studies; inclusions: 
BCRL, described HRQOL 
outcomes among BCRL, 
English only, formally 
developed, valid PROs. 
Exclusion: No conference 
abstracts, no BC in men 
 
 
 
 
 
 4 generic 
HRQOLs, 9 
oncology-
specific, 2 
BCRL-specific 
ULL-27 recommended b/c of 
strong psychometric 
properties, generic PRO 
should be used alongside 
condition-specific PRO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BCRL only, English only,  
women only. No non-
validated, modified 
standardized instrument. 
The article did not contain list 
of databases used for 
identifying articles.  
 
LYMPHEDEMA HRQOL ASSESSMENTS   24 
 
Treanor & 
Donnelly (2015), 
QLR 
Review studies 
investigating the 
validity, 
reliability, and 
sensitivity of the 
SF-36 and its 
derivatives 
among BC 
survivors. 
Systematic 
Review 
AOTA level: I 
Pyramid  level: 
D1 
Papers included: 7 
PubMed, MEDLINE, 
EMBASE, CINAHL, 
PsycINFO and the Social 
Sciences Citation Index 
search engines were used 
with keyword search terms. 
Reference lists of retrieved 
articles were reviewed for 
relevant contributing 
articles. 
Inclusion criteria: 
Articles including survivors 
of BC; using SF measures to 
assess psychometrics of 
other measures, peer-review 
articles 
Exclusion Criteria: 
No exclusions were made 
due to the small number of 
papers identified 
SF-36  
partial SF-36  
SF-12  
FACT-B 
FACT-G 
  
Internal Consistency: 
SF-36 and SF-12 subscales 
ranged from acceptable to 
good across different 
language and ethnic groups.  
Concurrent validity: 
Good inter-correlation 
between Dutch SF-36 and 
lymphedema-specific 
measures (ULL27 and 
Lymp-ICF), but less strong 
correlation with physical 
subscales. SF-36 
discriminated between BC 
survivors w/ and w/o 
lymphedema on physical 
subscales. 
Conclusions: SF measures 
were found to have good 
psychometric properties and 
would provide a useful aide 
for health care providers to 
assess health-related 
outcomes of breast cancer 
survivors in their care. 
Further research needed to 
identify psychometric 
performance of SF-36 on 
cancer-related effects. 
 
 
Articles which scored ‘poor’ 
on one item on the COSMIN 
checklist may have received 
an overall ‘poor’ rating. 
Inclusion of additional studies 
which did not primarily assess 
psychometric properties of SF 
may be questionable. Many 
psychometric properties of the 
SF-36 were not assessed in the 
breast cancer population. 
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Summary of Study Designs of Articles Selected for the CAT Table 
Pyramid Side Study Design/Methodology of Selected Articles Number of 
Articles 
Selected 
Experimental ___Meta-Analyses of Experimental Trials 
___Individual Randomized Controlled Trials 
___Controlled Clinical Trials 
___Single Subject Studies 
 
 
Outcome ___Meta-Analyses of Related Outcome Studies 
___Individual Quasi-Experimental Studies 
___Case-Control Studies 
___One Group Pre-Post Studies 
 
Qualitative ___Meta-Syntheses of Related Qualitative Studies 
___Small Group Qualitative Studies 
___brief vs prolonged engagement with participants 
___triangulation of data (multiple sources) 
___interpretation (peer & member-checking) 
___a posteriori (exploratory) vs apriori (confirmatory) 
interpretive scheme 
___Qualitative Study on a Single Person 
 
Descriptive _4_Systematic Reviews of Related Descriptive 
Studies 
15_Association, Correlational Studies 
___Multiple Case Studies (Series), Normative Studies 
___Individual Case Studies 
 
19 
Comments: 
The majority of studies were correlational studies evaluating psychometric 
properties. Four studies were literature or systematic reviews comparing 
psychometrics across assessments. 
AOTA Levels 
I- 4 
II-  
III- 
IV- 15 
V- 
TOTAL =19 
 
Abbreviation Full Phrase 
1° Primary 
2° Secondary 
ACS Patient's arm comfort scale 
ALMANAC Axillary lymphatic mapping against nodal axillary clearance 
BC Breast cancer 
BCRL Breast cancer related lymphedema 
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COSMIN Consensus-based Standards for the Selection of Health Measurement Instruments 
DASH Disability of Arm, Shoulder, and Hand 
EDGE Evaluation database to guide effectiveness 
EMR Electronic medical record 
EORTC QCQ-
BR23 
European Organization for Research and Treatment of Cancer-specific quality of life 
questionnaire- breast cancer 23 
EORTC QCQ-C30 European Organization for Research and Treatment of Cancer-specific quality of life 
questionnaire-cancer 30 
EWB Emotional well-being 
FACT-B, FACT-
B+4 
The Functional Assessment of Cancer Therapy - Breast 
FACT-G Functional Assessment of Cancer Treatment - General 
FLIC Functional Living Index-Cancer 
FWB Functional well-being 
GCI Global clinical impression 
GSI Global symptom index 
HADS Hospital Anxiety and Depression Scale 
HOS Health outcome survey 
HRQoL Health-related quality of life 
IBCSG International Breast Cancer Study Group 
ICC Intra-class correlation 
LE Lower extremity 
LEFS Lower extremity functional scale 
LLIS Lymphedema Life Impact Scale 
LSQ-32 Life Satisfaction Questionnaire – 32 
Lymph-ICF Lymphoedema Functioning, Disability, and Health Questionnaire 
Lymph-ICF-LL Lymphoedema Functioning, Disability, and Health Questionnaire for Lower Limb 
Lymphedema 
LYMQOL Lymphedema Quality of Life Measure for Limb 
LyQLI Lymphedema Quality of Life Inventory 
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MCID Minimal clinically important difference 
MCS Mental component summary measure 
NHP Nottingham Health Profile 
PCS Physical component summary measure 
PSR Performance status rating 
PRO Patient reported outcomes 
PWB Physical well-being 
QLICP-BR Quality of Life Instrument for Cancer Patients-breast cancer 
QoL Quality of life 
SD Standard deviation 
SEM standard error of measure 
SF Short Form 
SF-12 Short Form-12 
SF-36 Short Form-36 
SFWB Social and family well-being 
SLQOLI Swedish Lymphedema Quality of Life Inventory 
TOI-PFB Trial Outcome Index – Physical/Functional/Breast 
UE Upper extremity 
UK United Kingdom 
ULL-27 Upper limb lymphedema measure 
w/ With 
w/o Without 
yo years-old 
 
Summary of Key Findings: 
Summary of Experimental Studies 
N/A   
 
Summary of Outcome Studies 
N/A   
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Summary of Qualitative Studies 
N/A  
 
Summary of Descriptive Studies 
The DASH questionnaire consists of 30 items that evaluate symptoms and functional tasks associated with 
limitations in the arm, shoulder, and hand. It demonstrated strong reliability, validity, and sensitivity to change 
in women with BC. The tool has been widely used in BC research and clinics on patients with and without 
lymphedema since its inception in the mid-1990s (Coster, Poole, & Fallowfield, 2001; Davies et al., 2015). 
 
The Functional Living Index-Cancer (FLIC) is a broad-based assessment tool developed in the early 1990s to 
measure HRQoL for patients with cancer. The physical function domain of the assessment discriminates 
patients diagnosed with lymphedema. The instrument is more sensitive to emotional well-being than the SF-
36 (Morrow, Lindke & Blacke, 1992; Wilson, Hutson & VanStry, 2005).  
 
The FACT-B+4 consists of 36 items with four questions addressing swelling and tenderness in the arm. It was 
developed to supplement the FACT-B, the original multi-dimensional breast cancer QoL tool. It has been 
tested on women with lymphedema secondary to BC. This tool has strong reliability, internal consistency, and 
sensitivity to change over time with women with BC (Brady et al., 1997; Coster, Poole, & Fallowfield, 2001; 
Davies et al., 2015). 
 
The LLIS is a new lymphedema-specific assessment tool designed for use in the U.S. for calculating G-codes. 
The LLIS was compared to the LYMQOL, EORTC QLQ30, DASH, and LEFS and demonstrated good 
validity and reliability for assessing lymphedema severity among adult patients (Weiss & Daniel, 2015).  The 
LLIS correlated more strongly with the LYMQOL than the others, except for the functional domain of the 
DASH. A limitation was a sample comprised largely of white females (Weiss & Daniel, 2015). 
 
The LyQLI is a new lymphedema-specific Swedish assessment tool adapted from the SLQOLI as of 2015. It 
was compared to the SF-36 and shown to have good reliability and validity. Results indicate that the 
assessment tool holds promise. Sensitivity not tested (Klernas, Horstmann, &  Kristjansson, 2015). 
 
The Lymph-ICF was created in 2011 for patients with upper limb lymphedema (Devoogdt et al., 2011). Initial 
psychometric testing revealed strong test-retest reliability, internal consistency, content validity, and construct 
validity when compared against the SF-36 (Davies et al., 2015; Devoogdt et al., 2011). Women and Dutch 
populations were predominantly studied when establishing psychometric properties of this measurement 
device. There is no evidence of clinical use in the U.S. (Davies, 2015). 
 
The Lymph-ICF-LL was created in 2014 for patients with lower limb lymphedema (Devoogdt et al., 2014). 
Initial psychometric testing demonstrated that it was a reliable and valid measure, but similar to the Lymph-
ICF, this instrument has only been tested on Dutch populations with lymphedema secondary to axillary 
dissection (Devoogdt et al., 2014).  
 
The ULL-27 was developed in France in 2002 for measurement of upper limb lymphedema. It tests physical, 
social, and psychological domains. Initial testing of the psychometrics report that the test is reliable, 
consistent, and responsive to change (Launois et al., 2002). This measurement tool has been translated into 
English and Dutch, but only the Dutch version has undergone psychometric testing after adaptation and 
translation (Davies et al., 2015). The Dutch version translation demonstrated internal consistency on all items 
with exception of two questions which are addressed by Viehoff, Van Genderen, and Wittink (2008). The 
physical domain of this version poorly correlated to the SF-36 (Viehoff et al., 2008).  
 
The LYMQOL’s psychometrics were listed by a secondary study, but the primary study was not obtained 
through available resources. However, a Dutch version that tested psychometric properties demonstrated good 
validity and reliability for assessing HRQoL in patients with lower limb lymphedema (Van de Pas, Biemans, 
Boonen, Viehoff, & Newmann, 2015). The LYMQOL was developed with a structure similar to EORTC 
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QLQ-C30. Results state assessment is a validated QoL for use with persons with lymphoedema, and 
systematic review cites similar findings (Davies, Ryans, Levenhagan, & Perdomo, 2014). 
 
The EORTC developed the QLQ-C30 and the QLQ-BR23 to measure quality of life among patients with BC. The 
test has been translated to various languages and in one study demonstrated good reliability, clinical, and cross-
cultural validity for the Dutch, Spanish, and American versions (Sprangers et al., 1996). 
 
Implications for Consumers: 
While secondary lymphedema is often associated with patients undergoing cancer treatment, it is also 
experienced as a result of trauma or parasitic infection or where there is damage to the lymphatic 
system (Morgan, Franks, & Moffatt, 2005). Swelling, skin changes, fibrosis, sensory impairments, pain, 
discomfort, heaviness in the affected limb, and secondary infections are common symptoms associated with 
lymphedema (Morgan et al., 2005). Understanding the HRQoL for patients with lymphedema is consistent 
with client-centered treatment. Since improvement of HRQoL is the primary aim of lymphedema treatment, it 
is imperative that valid and reliable measures are used to best capture this condition-specific experience. This 
critical appraisal demonstrates that outcome measurements for lymphedema treatment are varied in their 
approach (generic versus condition-specific) and include different areas of HRQoL. Consumers should take 
note of the types of outcome measures used by lymphedema therapists during treatment and evaluate the 
accuracy of results against subjective experience. If a patient with lymphedema feels that outcomes are not 
consistent with instrument results, or that a selected measure is not appropriate for his or her case, this 
critically-appraised topic can serve as a resource for advocacy. A patient with lymphedema should advocate 
for the most valid and reliable measurement of outcomes for purposes of adjusting treatment for optimal 
gains. 
 
Implications for Practitioners: 
This critically appraised topic is especially important to occupational therapists specializing in lymphedema. 
The 2013 mandate by Medicare to report G-codes, a functional status for patients across points of treatment, 
highlights a trend towards defining successful treatment as it relates to function (Doucet, 2014). This focus 
on functional activities has been a tenet of occupational therapy since its inception. Doucet (2014) describes 
this as a “critical” time for occupational therapists to assert the unique scope and domain of function in their 
practice. In order to capitalize on this opportunity, the use of valid and reliable measures to document 
function is essential. Psychometrically-sound measurement instruments arm practitioners with objective data 
to quantify the effectiveness of interventions on everyday functioning. This information works to 
demonstrate the effects of treatment to third-party payers for purposes of reimbursement.  
Practitioners specializing in lymphedema therapy define function as it relates to HRQoL. Hence, it is 
fundamental for this sub-field of occupational therapy to incorporate outcome measures that reliably and 
accurately target condition-specific HRQoL. Since research on condition- specific measurements is still in its 
infancy, practitioners should evaluate the characteristics of each device against a client's specific 
presentation (i.e., comorbidities, upper limb versus lower limb, etc.) to select the most appropriate 
measurement tool. Practitioners working with female patients experiencing lymphedema in the upper limb 
secondary to BC will have a stronger body of evidence-based outcome measures to select from (FACT-B+4, 
EORTC QLQ-BR23) (Coster et al., 2001; Oliveira et al., 2015; Patoo, et al., 2015).  
Practitioners should stay abreast of research developments surrounding this topic since the recent influx of 
promising lymphedema-specific measurements and cultural adaptations for these measures indicate that 
further psychometric testing is underway (Devoogdt et al., 2014; Launois et al., 2002; Oliveira et al., 2015; 
Viehoff et al., 2008).  
Program development that establishes protocols for selecting outcome measurements used during evaluation 
and assessment would be appropriate based on this critically-appraised topic. In conclusion, this critically-
appraised topic supports the use of the DASH for patients with lymphedema when lymphedema is secondary 
to breast cancer. For patients with lymphedema not secondary to BC, this critically-appraised topic 
recommends adoption of the LLIS. Future program development is recommended to outline decision-making 
protocols for outcome measures that are awaiting further psychometric testing (Lymph-ICF, Lymph-ICF-LL, 
LyQLI, & ULL-27). Development of these protocols will allow all lymphedema patients within a setting to 
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be assessed with reliable and valid measures in a consistent manner. In addition, implementing these 
assessments in a systematic way will provide cohesion across therapists and settings and communicate 
intervention outcomes with a variety of disciplines along the continuum of care. 
 
Implications for Researchers: 
This critically-appraised topic has multiple implications for researchers. Due to the limited amount and types 
of research surrounding each lymphedema-specific measure, further research is needed to evaluate the 
psychometric properties of the LLIS, Lymph-ICF, Lymph-ICF-LL, LYMQOL, and ULL-27. Furthermore, 
there is a need for studies addressing the cultural adaptation and translation for these types of measures 
(Oliveira et al., 2015). Overall, it appears that generic measurements such as the SF-36 and DASH are reliable 
and valid for assessing HRQoL, and are often used as a comparison against newer measurement tools (Davies 
et al., 2015; Devoogdt et al., 2014; Launois et al., 2002; Viehoff et al., 2008, etc.). Through the use of well-
studied generic tools, researchers should investigate the aforementioned lymphedema-specific measurements 
and encourage further development for distinct characteristics of HRQoL in patients with lymphedema. This 
will provide practitioners with measures that objectively demonstrate the effects of intervention as related to 
function during a time of utmost importance (Doucet, 2014). 
 
Bottom Line for Occupational Therapy Practice/ Recommendations for Better Practice: 
Occupational therapists specializing in lymphedema can apply information from this critically-appraised 
topic to better inform decisions when selecting outcome measures on a patient’s HRQoL. Lymphedema-
specific measurement devices are ideal for most accurately quantifying results of therapy (Launois et al., 
2002), but many are still awaiting adequate psychometric backing for full implementation at this time. The 
DASH, a generic HRQoL measure that is widely used in practice, has demonstrated excellent reliability and 
validity on women with lymphedema secondary to BC (Davies et al., 2015). This critically-appraised topic 
implies that better practice in lymphedema therapy can be obtained by implementing this generic HRQoL for 
use with patients with BC. For patients who do not have lymphedema secondary to BC, it is recommended to 
use a lymphedema specific HRQoL measure to obtain a more specific and personalized picture of the impact 
that lymphedema has on the patient. Thus, for these purposes, the research indicates that the LLIS is 
currently the best route, excluding use with patients with BC for which the DASH would be a better 
assessment tool. These conclusions were reached after reviewing psychometric properties, ease of clinical 
use, and generalizability to populations in the U.S. With further testing in the U.S., the FACT B +4 could be 
a viable option for patients experiencing lymphedema secondary to BC. Further details on the data used to 
reach these recommendations are presented in Table 1. 
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Involvement Plan 
In 2013, Medicare mandated that therapists report G-codes, a functional status code for patients across 
points of treatment. Our review, which revolved around evaluating psychometrically-sound measurement 
instruments used by lymphedema specialists to measure HRQoL, led to the recommendation of two assessments: the 
DASH and the LLIS. In deciding upon the best route to translate knowledge gained from our research, we met with 
Heidi Shaffer, our collaborating clinician for this project. The process for our involvement plan has been outlined in 
Table 2. We began our dialogue with Heidi around the fact that the Gig Harbor Lymphedema MultiCare clinic 
already purchased the LLIS, a lymphedema-specific measurement tool. In highlighting this fact to Heidi, we learned 
of current obstacles to full implementation of this assessment. 
As Heidi explained, the LLIS G-code calculator was not embedded into Epic®, the EMR system used by 
MultiCare, making the assessment difficult to utilize. Currently, some therapists substitute this standardized 
assessment with their clinical reasoning and a G-code calculator independently created by MultiCare for reporting 
G-codes.  Heidi indicated that the LLIS had been requested to be inputted into the computer system, but the request 
had not yet been implemented. Hence, even though the LLIS has its own G-code calculator, it was not readily 
available for all clinicians to use due to the fact that their computer system had not been updated. At this point in our 
conversation, Heidi pointed out that Sherri Olsen, Director of Physical Medicine and Rehabilitation, would be the 
appropriate person to talk to about our knowledge translation process to implement our recommendations. Related 
tasks and products for this meeting are detailed in Table 2, Items 1-2. 
The other assessment recommended by our research was the DASH, a generic upper extremity HRQol tool 
which does not come with its own G-code calculator. Heidi was excited about the idea of creating a G-code 
calculator for this assessment in order to promote its efficiency, but reiterated that we should meet with Sherri as a 
first step. Hence, we learned that we had an opportunity to introduce our knowledge translation plan to a person who 
could potentially facilitate a largescale change, but that a barrier existed in the process of embedding code into the 
Epic® computer system. This added a new dynamic to our knowledge translation process as we considered how to 
best present our research to Sherri to effect change, and how we might be involved with this third party of computer 
technicians. 
Next, Heidi suggested we provide an in-service presentation and printed materials to MultiCare 
lymphedema therapists to describe administration of the DASH and the LLIS. She thought that outlining the pros 
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and cons for each assessment in addition to providing a pamphlet that therapists could quickly refer to would be 
helpful. These next task steps and products are elaborated upon in Table 2, Item 3. 
Finally, we discussed the possibility of presenting our findings at an AOTA conference. To this end, Heidi 
recommended we also look into submitting our research to the National Lymphedema Network Conference 
scheduled for 2018. This last step is outlined in Table 2, Item 4. 
As evident from our conversation with Heidi, there are contextual factors to our knowledge translation 
process that we had not previously accounted for. As clinical use of an assessment is largely dependent on its 
usability within an electronic documentation system, there are cultural, technical, and administrative factors not only 
within the MultiCare organization itself, but also within the Epic® organization to consider.  We felt that if we were 
able to effect change on an organizational level by integrating the LLIS and DASH assessments into the 
documentation system, there would remain individual factors to analyze. Current practice of applying clinical 
reasoning to produce HRQoL descriptions and corresponding G-codes implies that an internal process exists that 
may be difficult to change. Thus, our knowledge translation may have been affected by the long held practices of the 
lymphedema therapists themselves, which is consistent with the ARC model for knowledge translation (as cited in 
Palinkas & Soydan 2012).   
While these contextual factors presented possible barriers, they also provided valuable information to 
inform our strategy and planning process. Upon meeting with Sherri, we had planned to inquire as to how we could 
best aid in pushing Epic® to embed the two assessments and their corresponding G-code calculators into the 
computer system. During our in-service presentation and through distribution of printed materials, we demonstrated 
that adoption of the DASH and LLIS supports evidence-based practice and, each with its own G-code calculator, 
will aid in the efficiency of the practicing clinicians. If we pursue an application to the National Lymphedema 
Network conference and AOTA conference, we hope to further impart this knowledge translation to a wider 
audience. In terms of evaluating the outcomes of these various activities, we followed up with a satisfaction survey 
at the end of our in-service presentation. 
 
Knowledge Translation Activities and Products 
The main goal of our knowledge translation process was to come ‘full circle’ by applying our evidence-
based recommendations to G-codes for Medicare reporting, as this was a piece of the original research question 
from our collaborating clinician. Calculating accurate G-codes rests on the use of psychometrically sound 
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assessments, thus we felt G-codes would also be a logical avenue to bring about evidence-based change for the 
MultiCare lymphedema therapists. After meeting with Heidi on February 13, 2017 we learned that neither the LLIS 
nor the DASH were features of Epic®, the electronic medical records system used by MultiCare lymphedema 
therapists. To increase the ease in utilizing our recommended standardized assessments, we established a second 
goal for our knowledge translation process: to make these two assessments readily available within the Epic® 
system. After hearing about this proposal, Heidi recommended we meet with Sherri Olsen to discuss the process to 
bring about this change.  
The first stage of our knowledge translation process aimed to create a G-code calculator for the two 
recommended assessments used to measure HRQoL for patients with lymphedema: the LLIS and the DASH. We 
learned that the LLIS has a G-code calculator embedded within its e-format, but clinicians at MultiCare did not have 
a readily available G-code calculator for the DASH. Upon researching G-code calculations, we quickly learned that 
G-code modifier “cheat sheets” had already been created for a variety of assessments. As the DASH produces a 
score on a 100 point scale and modifiers are coded in units of 10 from 1 to 100, converting DASH assessment scores 
to a G-code modifier score was more of a seamless process than we anticipated. We verified our findings, 
reproduced the calculations, and distributed small laminated copies of the DASH ‘cheat sheets’ for clinicians during 
our in-service presentation. This was the first product of our knowledge translation process.  
During an in-service presentation held at Tacoma General Hospital, we spent about 30 minutes with eight 
practitioners highlighting our research and the take-aways from our findings. We prepared a PowerPoint 
presentation to aid us in explaining our research process, findings, and implications, but experienced technical 
difficulties in showing this during our presentation. As a result, we forwarded a copy of the PowerPoint presentation 
to Heidi and Sherri following the in-service. While conversing with the lymphedema therapists, we learned that 
standardized assessments are typically administered to patients on a laminated copy followed by the therapists’ entry 
of the scores into Epic®. We also learned that therapists often use the Quick DASH in lieu of the DASH, an 
assessment our research review did not cover. While these two unexpected hurdles arose during our in-service 
presentation, the therapists seemed very interested in the table we had created and very receptive to the information 
provided regarding the recommended assessments. A satisfaction survey was used to gauge the delivery and utility 
of the information presented. This in-service presentation, accompanying PowerPoint, and satisfaction survey served 
as the second piece of our knowledge translation process.   
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The final stage of knowledge translation for this research revolved around an hour long meeting with Sherri 
at the University of Puget Sound campus on April 14, 2017 with George Tomlin, our facilitating faculty member. 
We found this meeting to be integral for obtaining insight into the realities for practicing lymphedema therapists. 
Sherri described that a common barrier to accessing lymphedema therapy services often lies in the referral process 
from oncologists. She explained that doctors are often concerned about the load of appointments that their patients 
must attend and often do not always understand the role of occupational and physical therapy in addressing 
lymphedema at the critical juncture early on in their diagnosis. Often, she explained, patients do not experience 
lymphedema until weeks or even months after seeing their doctor, and thus lymphedema therapy does not become 
an immediate issue for them to address. Sherri explained her involvement in current research regarding “prehab” for 
lymphedema treatment, and the desire to provide hard evidence showing the benefits of therapy early on to doctors. 
She explained that our research concerning HRQoL for patients with lymphedema has aided her in the early process 
of her research to identify a HRQoL measure for use in her study. While this confirmed the utility in our research 
implications for other researchers, this meeting also revealed an unexpected difficulty to our knowledge translation 
process as related to the bigger picture that practitioners work in: if clients are not receiving therapy services until a 
more chronic stage in the course of their lymphedema, then an HRQoL is less likely to demonstrate changes in 
function along the course of therapy in the way that it likely would if patients were referred earlier in the course of 
lymphedema management. Overall, this could potentially lead to a smaller change in function as illustrated by G-
code reporting when, in actuality, the lack of change is a result of the late referral to therapy. This meeting brought a 
new perspective to how our research, a piece of the puzzle that is the world of lymphedema therapy, exists in 
relation to larger systemic forces at play.   
In addition to this insight, meeting with Sherri allowed us to follow up on our final goal of knowledge 
translation: to facilitate making the DASH and LLIS readily available within the Epic® system. Sherri suggested we 
craft an email with detailed instructions that she could forward to the infomatic specialists at Epic®. This email 
became the final step in our knowledge translation process. A remaining unforeseen difficulty in this process lies in 
not knowing if the Epic® computer programmers were successful in implementing our directions and if they were, 
how therapists understood or were informed about this new feature incorporated into Epic®. We also had not 
anticipated the amount of time and effort involved in preparing an email with explicit, detailed information to 
program the assessments into Epic®, and imparting a change to the way standardized assessments are administered 
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by lymphedema therapists. Effective knowledge translation requires not only communication amongst multiple 
parties for coordination purposes, but also education on processes (e.g. scoring the DASH, psychometric properties 
of each assessment, etc.) to ensure fidelity.  
Additional pieces of our knowledge translation include submitting our findings to the 2018 AOTA 
conference next year, which we intend to complete in May when the AOTA submission guidelines become 
available. We located information about to the National Lymphedema Network. However, we were unable to locate 
specific information regarding submission of research.  
Knowledge Translations Outcomes 
At the end of our in-service presentation to the lymphedema therapists at MultiCare, we handed out a 
satisfaction survey to gauge the delivery and utility of the information presented on our research findings. The 
survey also provided the therapists on opportunity to reflect on their current practices and any barriers they may face 
in implementing our findings. In addition, we crafted an email with detailed instructions addressed to Sherri that she 
could forward onto the informatics specialists at Epic® that would allow the LLIS and the DASH along with their 
G-code calculators to be embedded into the computer system for ease of use. We plan to monitor the outcomes of 
this last piece of knowledge translation by remaining in contact with Sherri and Heidi via email in regards to 
progress of embedding these assessments into Epic®. 
Knowledge Translation Effectiveness 
The purpose of our knowledge translation process was twofold: to inform clinicians of current evidence on 
lymphedema HRQoL assessments and to motivate change within the MultiCare organization towards using 
recommended assessments. An in-service presentation was the primary vehicle to enact both of these goals. For the 
second phase of our process, we used an active strategy of writing directions to be e-mailed to informatics specialists 
at Epic®. This was intended to promote change in current practices. Since this latter stage is still underway, we have 
not yet been able to evaluate the effectiveness of this change. In order to measure the effectiveness the first phase of 
the knowledge translation process, a satisfaction survey was implemented, the results of which informed our 
conclusions. .  
The satisfaction survey was created for our in-service presentation to the MultiCare lymphedema specialists 
and was completed by six of the seven therapists who attended the presentation (one attended via conference call). 
The survey consisted of five quantitative statements using a Likert scale ranging from strongly agree to strongly 
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disagree and three qualitative questions. All of the respondents rated four of the five statements as strongly agree or 
agree. These statements included: (1) The information presented today was helpful for my clinical practice, (2) I 
understand the different situations for which the DASH and the LLIS are recommended, (4) I feel more informed 
about current research around lymphedema HRQoL assessments after this in-service, (5) The research process, 
results, and conclusions were clearly and professionally presented. The last three qualitative questions asked 
included: (6) Was there any information that was not covered for which you would have liked to know more about? 
(7) What barriers do you anticipate in implementing use of the LLIS or DASH? (8) Do you have any additional 
questions, comments, concerns, or suggestions related to this research? The results of this satisfaction survey 
provided a means for measuring the first phase of our knowledge translation process. 
We were successful in some of our knowledge translation tasks and only partially effective in others. We 
met the objective of educating clinicians on psychometric data for HRQoL assessments. This was measured by items 
(2), (4), and (6) of the satisfaction survey which targeted the degree to which clinicians felt informed after the in-
service presentation. All six respondents noted “agree” on (4) and (6) indicating that they felt more informed after 
participating in our in-service presentation. Item (6) was left blank on all surveys, signaling that clinicians did not 
feel there were gaps in the topics covered. Based on these results, we can conclude that we adequately informed 
clinicians and that data regarding psychometric standing of lymphedema HRQoL assessments was sufficiently 
translated. 
The objective to motivate change within the MultiCare clinic was carried out through our in-service 
presentation, creation and delivery of G-code modifier “cheat sheets,” and by taking steps toward incorporating the 
recommended assessments into Epic®. The following items of the survey targeted this domain: (3) I plan to use the 
DASH with the G-code modifier card in clinical practice and item (7) What barriers do you anticipate in 
implementing use of the LLIS or DASH? Item (3) received one response of “strongly agree,” one response of 
“agree,” three “neutral,” and one response of “disagree.” Barriers listed in item (7) were “facial edema patients,” 
“time concerns,” “duration of session,” and “don’t use LLIS.” As the majority of clinicians felt neutral or disagreed 
with the statement regarding their intent to use the DASH and G-code modifier card, we concluded that most 
clinicians did not find the G-code modifier card useful and that they were unlikely to begin using the DASH if they 
were not already. Barriers listed surrounding the element of time in a therapy session and the types of diagnoses that 
the DASH and LLIS do not address further implied that our in-service presentation had not effectively considered 
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these important factors when making recommendations. The issue of time efficiency arose during a question and 
answer period during the in-service when a clinician inquired about research on the Quick DASH; an assessment we 
had not encountered in our search. Based on this feedback, we have concluded that we have not yet met our second 
objective in our knowledge translation for motivating change within MultiCare. 
The goal to ignite change was elaborated on by composing an email to Epic® programmers about 
embedding a feature for scoring and calculating G-codes for the DASH and LLIS in the Epic® system. As this email 
has only recently been submitted, we plan to measure our effectiveness through follow up correspondence with 
Sherri. Specifically, we plan to inquire about a response from programmers, if clinicians are administering HRQoL 
assessments as recommended, and how clinicians will be informed of the new features in Epic®. These final stages 
will allow us to evaluate our impact on motivating an adoption of the DASH and LLIS at the MultiCare clinic. 
It has been reported that there is often a gap lasting up to 20 years between establishing evidence and 
implementing or translating this knowledge into practice (as cited in Palinkas & Soydan, 2012). In order to address 
this issue and widen the audience to whom our research is intended, a final element of our process has been to 
submit our findings to AOTA for a poster presentation at their 2018 conference. For this step, we have drafted a 
submission proposal for our research. We plan to submit this around the time that the application period opens 
beginning May 1. Measuring effectiveness of this process will obviously take place at a future date and will likely 
involve a satisfaction or impact survey at the conference should the proposal be accepted. This final step will 
attempt to correct the issues we found to be ineffective during our in-service at MultiCare and will serve as an 
attempt to translate our knowledge on a larger scale.  
Evaluation of Overall Process of Project 
The process of this critically appraised topic has been instrumental in building a sense of identity as 
occupational therapists.  As the project occurred in tandem with our learning about occupational therapy via 
participation in an entry level master’s degree program, this research project has provided a framework of the 
process involved to be an evidence-based practitioner. As we arrive towards the end of this journey, we are able to 
better reflect on this process.  
We began with a research question that sought to understand the utility of G-codes in a lymphedema setting 
and were quickly discouraged by the initial search result of one article in the databases that used the words “G-
codes”  in a way that was relevant to occupational therapy. Upon meeting with our project chair who was an expert 
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on the content related to this topic, we were able to expand the way we conceptualized G-codes by focusing on the 
elements of function that G-codes were targeting. The guidance we received from our project chair during this phase 
led us to a new search strategy that operationalized G-codes via HRQoL assessments used in lymphedema therapy. 
This step enabled us to “cast a wider net” within our search strategy that was appropriate for critical analysis and 
tied back to our collaborating clinician’s initial question. In practice, this stage may represent an identification of a 
problem or need for further understanding around practice trends. 
After identifying the most appropriate HRQoL assessments to include in our research, we dissected them 
for their reports of psychometric data to include in a CAT table format. This stage required us to consider and 
analyze the research practices involved in each study for a succinct report and overall evaluation. While it felt 
tedious and required meticulous attention to each article, the skills used during this phase will be required to 
independently access information as practitioners. This stage also required us to continually evaluate the relevance 
of articles in relation to our search criteria.  
The final stage in this research project surrounding knowledge translation has allowed us to stand back and 
understand how our findings fit into the bigger, ‘real world’ picture of lymphedema therapy. Meeting with a team of 
lymphedema practitioners during our in-service presentation and then following up individually with Sherri Olsen 
has led us to understand emerging areas for research, barriers to implementing evidence-based practice, and how 
systemic factors such as the referral process to lymphedema therapy work to affect G-code scores. This stage was a 
valuable first experiment in learning how to bring research most efficiently into a practice setting. We learned that 
delivery needs to be engaging, motivating, and coordinated by thoughtful and efficient communication with multiple 
parties.  
In all, this project has been an important element in our growth as it has armed us with the tools required 
and the firsthand knowledge needed to be evidence-based practitioners. While much of learning within an academic 
program revolves around individual enrichment and scholastic endeavor, this project allowed us to contribute to the 
field of occupational therapy as a whole as well as providing valuable education and artifacts to local community-
based practitioners within a particular hospital organization. We hope to continue to give back to our profession and 
its stakeholders in similar ways throughout our career in the years to come. 
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Recommendations for Future 
As noted previously in our recommendation for researchers, several lymphedema-specific assessments 
(Lymph-ICF, Lymph-ICF-LL, LYMQOL, & ULL-27) are still awaiting adequate psychometric backing for full 
implementation in the U.S. population at this time. It would be prudent to revisit the original research question in 
four to five years’ time to determine whether there are changes to our current findings.  
During our meeting with Sherri, future research needs were discussed including the possibility of 
identifying HRQoL assessments for patients with specific diagnoses like cancer.  Applying the same research 
methodology and analysis used for this project could be applied to identify HRQoL assessments within a particular 
diagnostic population. Sherri noted that this information would be helpful evidence to justify use of specific HRQoL 
assessments. Furthermore, this could be instrumental in obtaining reliable outcome data for intervention research 
being conducted by MultiCare in collaboration with Seattle Cancer Care Alliance.  
The research Sherri is currently pursuing addresses the efficacy of prehab, proactive habilitation prior to 
radiation and chemotherapy treatments, for patients undergoing cancer treatment. Within this discussion, it was also 
noted that additional research could be conducted regarding the benefits of prehab services for a variety of 
diagnostic populations. This research would be best completed through a systematic review of the literature looking 
at the potential outcomes resulting from this intervention, potentially including reduced hospitalization and 
insurance costs, increased patient satisfaction, and improved HRQoL.   
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Appendix A 
Breast Cancer EDGE Task Force Rating Scale 
(Adapted from StrokEDGE form) 
Modification of Recommendation Scoring to be used with EDGE form submissions: 
 
4 = highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has 
been used in research on individuals with or post breast cancer.  
 
3 = recommended; the outcome measure has good psychometric properties and good clinical utility; no published 
evidence that the measure has been applied to research on individuals with or post breast cancer. 
 
2A = unable to recommend at this time; there is insufficient information to support a recommendation of this 
outcome measure; the measure has been used in research on individuals with or post breast cancer. 
 
2B= unable to recommend at this time; there is insufficient information to support a recommendation of this outcome 
measure; no published evidence that the measure has been applied to research on individuals with or post breast 
cancer. 
 
1 = not recommended; the outcome measure has poor psychometric properties and/or poor clinical utility.  
Note: Reprinted from Davies, C., Ryans, K., Levenhagen, K., & Perdomo, M. (2014). Breast cancer EDGE task 
force outcomes: Quality of life and functional outcome measures for secondary lymphedema in breast cancer 
survivors. Rehabilitation Oncology, 32, 7-12. 
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Appendix B 
Access to Recommended Assessments 
Website to request access to the LLIS and G-code calculator: 
 http://klosetraining.com/llis-and-g-code-calculator/ 
Website to download the DASH: 
 http://dash.iwh.on.ca/about-dash
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Appendix C 
G-code Modifier Card 
G-code Modifiers 
CN (100 %) - 100 
CM (80-99%) - 80-99 
CL (60-79%) - 60 - 79 
CK (40-59%) - 40-59 
CJ (20-39%) - 20- 39 
CI (1-19%) - 1-19 
CH (0%) - 0 
DASH SCORE  
[(sum of n responses) - 1] x 25 
             n 
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Appendix D 
PowerPoint Content from In-Service Presentation 
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Appendix E 
Satisfaction Survey 
Please circle the answer that best describes your feelings after this in-service presentation.  
 
1. The information presented today was helpful for my clinical practice. 
 
Strongly Agree    Agree        Neutral        Disagree    Strongly Disagree 
 
2. I understand the different situations for which the DASH and the LLIS are recommended.  
 
Strongly Agree    Agree        Neutral        Disagree    Strongly Disagree 
 
3. I plan to use the DASH with the G-code modifier card in clinical practice.  
 
Strongly Agree    Agree        Neutral        Disagree    Strongly Disagree 
 
4. I feel more informed about current research around lymphedema HRQoL assessments after 
this in-service. 
 
Strongly Agree    Agree        Neutral        Disagree    Strongly Disagree 
 
5. The research process, results, and conclusions were clearly and professionally presented.  
 
Strongly Agree    Agree        Neutral        Disagree    Strongly Disagree 
 
6. Was there any information that was not covered for which you would have liked to know more 
about? 
 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
7. What barriers do you anticipate in implementing use of the LLIS or DASH? 
 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
8. Do you have any additional questions, comments, concerns, or suggestions related to this 
research?  
 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
Thank you! 
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Appendix F 
Email to Sherri Olsen  
Dear Sherri, 
Thank you for your time in meeting with us today. We so enjoyed the opportunity to sit down and talk with you.  
With regards to our discussion about getting G-code calculations for the DASH and LLIS into the Epic® EMR 
system, here is what we recommend: 
-- 
For the LLIS, include a place in Epic® for the therapist to enter: 
1. The final score (0-68) 
2. The number of questions answered (0-17) 
3. Question #18 regarding infection occurrence requiring oral antibiotics or hospitalization (options are 0-4 times) 
4. Using the calculations in the attached Excel spreadsheet, have Epic® perform a calculation to convert the final 
score and number of questions answered into a single correlating Medicare modifier to be inputted into the patient’s 
record.  
*This in effect creates a G-code calculator directly into Epic®, bypassing the Excel spreadsheet G-code calculator 
that came attached with the LLIS.  
 
For the DASH, include a place in Epic® for the therapist to enter: 
1. The sum of responses (0-150) 
2. The number of questions answered (n=0-30) 
3. Have Epic® perform a calculation to convert the sum of responses and number of questions answered into a final 
score using the formula below.  
Formula: 
DASH Disability/Symptom Score = [((sum of n responses)/n)-1] x 25, where n is equal to the number of completed 
responses. 
4. Then convert the final DASH disability score into a single correlating Medicare modifier to be inputted into the 
patient’s record using the Medicare modifiers located in the attached Excel spreadsheet (e.g. 100% impairment (CN) 
correlates with a score of 100, 80% impairment (CM) correlates with a score of 80, etc.).  
5. Please provide a note for therapists: there must be at least 27 out of 30 responses answered to  complete the 
calculation. 
 
Additionally, include a place for the therapist to enter the optional subtest scores for: 
1. Work Module:  
The sum of responses (0-20) 
The number of questions answered (n=0-4) 
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2. Sports/Performing Arts Module: 
The sum of responses (0-20) 
The number of questions answered (n=0-4) 
For both of the optional modules, the final score is calculated with the formula below. 
Disability Score = [((sum of responses)/4)-1] x 25, where n is equal to the number of completed responses. 
*Please provide a note for therapists that all 4 of the optional responses must be answered to be calculated for each 
subtest. 
 
These calculations for both the LLIS and the DASH should be accessible for therapists to document in evaluation, 
progress, and discharge reports. 
 
 
 
 
LYMPHEDEMA HRQOL ASSESSMENTS   50 
 
Table 1. Overview of HRQOL Assessments Analyzed 
 Type of assessment Areas Assessed 
Psychometrics Study Clinical 
Utility 
 
Assessment 
Lymph
edema 
Cancer 
Breast 
Cancer 
Generic 
UE 
& 
LE 
Only 
UE 
Categories/Subscales 
Test-
Retest 
Reliability 
Intern
al 
Consis
tency 
Studi
ed in 
the 
U.S.? 
Study 
Populat
ion 
Time 
requi
red 
Avail
able 
EDGE 
Task 
Force 
Rating
* 
DASH    x  x 
Social – Psychological 
– Physical functioning 
- Symptoms 
ICC=0.92-
0.97 
α=0.92
-0.97 
Y N=144 5-10 
min. 
Free 4 
EORTC 
QLQ BR23 
  x    
Functional: body 
image and sexuality – 
Symptoms: arm, 
breast, systemic 
therapy side effects 
Not tested α=0.46
-0.94 
Y Dutch=
70, 
Spanish
=168, 
U.S.= 
158 
  Not 
rated 
FACT-B   x    
Physical well-being – 
Social/family well-
being – Emotional 
well-being – 
Functional well-being 
ICC=0.85 α=0.62
-0.90 
Y N=47 
N=295 
5-10 
min. 
Free Not 
rated 
FACT-B+4 x     x 
Physical well-being – 
Social/family well-
being – Emotional 
well-being – 
Functional well-being 
– Arm morbidity 
ICC=0.97 α=0.83
-0.88 
N N=279 
N=29 
5-10 
min. 
Free 4 
FLIC  X     
Role – Sociability – 
Emotional – Current 
health – hardship – 
Nausea – Pain 
Not tested α=0.90
-0.94 
 N=489 
 
  Not 
rated 
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LLIS x    X  
Physical – 
Psychosocial – 
Functional concerns 
ICC=0.94-
0.98 
α=0.93 Y N=102 5-10 
min. 
Free Not 
rated 
Lymph-
ICF 
x     x 
Function: physical, 
mental – Activity and 
participation 
limitations: household, 
mobility, life domains/ 
social life 
ICC=0.93 α=0.92 N 
 
N=90 5 
min. 
 2A 
Lymph-
ICF-LL 
x    X  
Function: physical, 
mental – Activity and 
participation 
limitations: general 
tasks/ household 
activities, mobility, 
life domains/ social 
life 
ICC=0.93 α=0.82
-0.97 
N N=50 5-10 
min. 
 Not 
rated 
LYMQOL x    X  
Functional – 
Appearance/body-
image –  Physical 
symptoms – 
Emotions/mood 
ICC=0.80 α=0.80
-0.89 
N U.K.= 
209, 
Dutch=
60 
  1 
ULL-27 x     x 
Physical – 
Psychological – Social 
ICC=0.70-
0.86 
α=0.78
-0.93 
N N=301 
N=145 
11 
min. 
 2A 
*See Appendix A for EDGE Task Force Rating descriptions. 
**Other assessments that were not included in the table due to insufficient psychometric data: 
   SF-36  
   LYQLI 
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Table 2: Tasks, Products, and Target Dates for Knowledge Translation 
Task/Product 
(1a-f above) 
Deadline 
Date 
Steps w/ Dates to achieve the final outcome 
1. Create G-code Calculator for 
DASH 
April 4 
(Prior to meeting 
with Sherri) 
 Research G-code criteria (March 2) 
 Develop excel calculation sheet (March 23) 
 Compare results with LLIS calculator (April 
4) 
2. Meet Independently with Sherri 
Olsen 
Prior to April 
19th. 
 Email to set up meeting (March 15) 
 Meet with Heidi’s boss, Sherri to present our 
research and new G-code calculator. 
 Advocate for having the calculator 
programmed into their Epic® documentation 
system. 
3. In-service with MultiCare 
Lymphedema Therapists 
April 26th or 
May 3rd 
 Create a clinical reasoning guide for when to 
use the LLIS or DASH   
 Visual aid (PowerPoint) on our findings 
 Satisfaction survey following presentation 
 (April 20) 
4. Submit to Nat’l Lymph. Network 
and/or AOTA 2018 conference 
TBD  Research requirements and deadlines for 
application process (March 20) 
 Create an abstract of our research paper 
(April 10) 
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Table 3: Knowledge Translation Completion Timeline 
Knowledge Translation Item Target Date Completion Date Notes 
G-code Calculator for the DASH 
 Research G-code criteria 
 Develop excel calculation 
sheet 
 Compare results with 
LLIS 
 
April 4, 2017 
 March 2, 2017 
 March 23, 2017 
 April 4, 2017 
March 26, 2017 
 March 10, 
2017 
 N/A 
 N/A 
Created laminated G-code 
modifier card for DASH in 
replacement of a G-code 
calculator.  
 
Meet independently with Sherri 
Olsen 
 Email to set up meeting 
April 19, 2017 
 March 15, 2017 
April 14, 2017 
 March 6, 
2017 & 
March, 
23, 2017 
 
Follow up email with 
directions to input 
assessments into Epic® 
delivered April 14, 2017. 
 
Plans to remain in 
communication via email in 
regards to implementation 
status.   
In-service for MultiCare 
Lymphedema Therapists 
 Clinical reasoning guide 
 PowerPoint on findings 
 Satisfaction Survey 
April 26/May 3, 2017 
 April 20, 2017 
 April 20, 2017 
 April 20, 2017 
March 29, 2017 
 N/A 
 March 26, 
2017 
 March 26, 
2017 
Clinician reasoning 
delivered through oral 
communication during in-
service.  
Submit to present at 2018 
conferences (AOTA 2018, NLN 
2019) 
 Research requirements 
 Create abstract 
TBD 
 March 20, 2017 
 April 10, 2017 
TBD 
 March 19, 
2017 
 April 7, 
2017 
Submission guidelines 
posted as of May 1, 2017 
for AOTA 2018 
conference.  
 
No data found regarding 
National Lymphedema 
conference.  
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